Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'
Vaccitech Hails Partner's ‘Aggressive’ Trial Design
The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.
You may also be interested in...
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
Oxford University vaccines expert Sarah Gilbert says the first UK vaccine candidate to prevent the SARS-CoV-2 coronavirus will begin clinical testing in healthy volunteers next week and that “prospects are very good” an effective COVID19 jab could be available by September.